Schuitemaker H - Search Results

1

Virus validation of pH 4-treated human immunoglobulin products produced by the Cohn fractionation process.

Bos OJ, Sunyé DG, Nieuweboer CE, van Engelenburg FA, Schuitemaker H, Over J. Bos OJ, et al. Among authors: schuitemaker h. Biologicals. 1998 Dec;26(4):267-76. doi: 10.1006/biol.1998.0148. Biologicals. 1998. PMID: 10403030

2

Viral safety of C1-inhibitor NF.

Terpstra FG, Kleijn M, Koenderman AH, Over J, van Engelenburg FA, Schuitemaker H, van 't Wout AB. Terpstra FG, et al. Among authors: schuitemaker h. Biologicals. 2007 Jun;35(3):173-81. doi: 10.1016/j.biologicals.2006.08.005. Epub 2006 Oct 30. Biologicals. 2007. PMID: 17071103

3

Potential and limitation of UVC irradiation for the inactivation of pathogens in platelet concentrates.

Terpstra FG, van 't Wout AB, Schuitemaker H, van Engelenburg FA, Dekkers DW, Verhaar R, de Korte D, Verhoeven AJ. Terpstra FG, et al. Among authors: schuitemaker h. Transfusion. 2008 Feb;48(2):304-13. doi: 10.1111/j.1537-2995.2007.01524.x. Epub 2007 Nov 19. Transfusion. 2008. PMID: 18028277

4

The virucidal spectrum of a high concentration alcohol mixture.

van Engelenburg FA, Terpstra FG, Schuitemaker H, Moorer WR. van Engelenburg FA, et al. Among authors: schuitemaker h. J Hosp Infect. 2002 Jun;51(2):121-5. doi: 10.1053/jhin.2002.1211. J Hosp Infect. 2002. PMID: 12090799

5

Inhibition of HIV-1 IIIB and clinical isolates by human parotid, submandibular, sublingual and palatine saliva.

Bolscher JG, Nazmi K, Ran LJ, van Engelenburg FA, Schuitemaker H, Veerman EC, Nieuw Amerongen AV. Bolscher JG, et al. Among authors: schuitemaker h. Eur J Oral Sci. 2002 Apr;110(2):149-56. doi: 10.1034/j.1600-0722.2002.11175.x. Eur J Oral Sci. 2002. PMID: 12013559

6

Low levels of human immunodeficiency virus type 1 DNA in high-risk seronegative men.

Koning FA, van der Vorst TJ, Schuitemaker H. Koning FA, et al. Among authors: schuitemaker h. J Virol. 2005 May;79(10):6551-3. doi: 10.1128/JVI.79.10.6551-6553.2005. J Virol. 2005. PMID: 15858041 Free PMC article.

7

Both R5 and X4 human immunodeficiency virus type 1 variants persist during prolonged therapy with five antiretroviral drugs.

van Rij RP, Visser JA, van Praag RM, Rientsma R, Prins JM, Lange JM, Schuitemaker H. van Rij RP, et al. Among authors: schuitemaker h. J Virol. 2002 Mar;76(6):3054-8. doi: 10.1128/jvi.76.6.3054-3058.2002. J Virol. 2002. PMID: 11861873 Free PMC article.

8

Increased in vitro cytopathicity of CC chemokine receptor 5-restricted human immunodeficiency virus type 1 primary isolates correlates with a progressive clinical course of infection.

Kwa D, Vingerhoed J, Boeser B, Schuitemaker H. Kwa D, et al. Among authors: schuitemaker h. J Infect Dis. 2003 May 1;187(9):1397-403. doi: 10.1086/374650. Epub 2003 Apr 9. J Infect Dis. 2003. PMID: 12717620

9

Isolation, propagation, and titration of human immunodeficiency virus type 1 from peripheral blood of infected individuals.

Schuitemaker H, Kootstra NA. Schuitemaker H, et al. Methods Mol Biol. 2005;304:17-24. doi: 10.1385/1-59259-907-9:017. Methods Mol Biol. 2005. PMID: 16061963

10

Susceptibility of recently transmitted subtype B human immunodeficiency virus type 1 variants to broadly neutralizing antibodies.

Quakkelaar ED, van Alphen FP, Boeser-Nunnink BD, van Nuenen AC, Pantophlet R, Schuitemaker H. Quakkelaar ED, et al. Among authors: schuitemaker h. J Virol. 2007 Aug;81(16):8533-42. doi: 10.1128/JVI.02816-06. Epub 2007 May 23. J Virol. 2007. PMID: 17522228 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

353 results

Search Page